10-Q: Certara Returns to Profit Amid Strong Revenue Growth

Certara, Inc. reported significant revenue increases and a return to net income for the first half of 2025, driven by robust demand and strategic acquisitions.

Summary

• Total revenues increased 12% to $104.6 million for the three months ended June 30, 2025, and 11% to $210.6 million for the six months ended June 30, 2025, compared to the same periods in 2024.
• Software revenues grew 22% in Q2 2025 to $46.7 million and 20% in H1 2025 to $93.1 million.
• Services revenues increased 5% in Q2 2025 to $57.9 million and 4% in H1 2025 to $117.5 million.
• Net income for the six months ended June 30, 2025, was $2.8 million, a significant improvement from a net loss of $17.3 million in the prior year period.
• The net loss for the three months ended June 30, 2025, narrowed to $2.0 million from $12.6 million in Q2 2024.
• Adjusted EBITDA increased 21.3% to $31.9 million in Q2 2025 and 20.4% to $66.8 million in H1 2025.
• Net cash provided by operating activities for H1 2025 was $35.2 million, up from $14.1 million in H1 2024.
• Bookings for Q2 2025 were $112.0 million, an increase from $98.9 million in Q2 2024.
• Organic revenue growth for H1 2025 was 5%, with acquisitions contributing 6% to total revenue growth.
• The company repurchased $25.0 million of common stock in Q2 2025 under a $100.0 million stock repurchase program, with $75.0 million remaining.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue growth, a return to net profitability for the half-year, and a substantial increase in operating cash flow. Strategic investments in AI and acquisitions are contributing to growth, and the stock repurchase program signals confidence. While net retention rates showed some variability, the overall financial health and strategic direction are very positive.

Positives

• Strong revenue growth across both software (22% in Q2 2025) and services (5% in Q2 2025) segments.
• Significant improvement in net income, moving from a substantial loss in H1 2024 to a profit of $2.8 million in H1 2025.
• Robust growth in Adjusted EBITDA, increasing over 20% for both the three and six months ended June 30, 2025.
• Substantial increase in net cash provided by operating activities, more than doubling from $14.1 million in H1 2024 to $35.2 million in H1 2025.
• Consistent growth in bookings, demonstrating strong demand and future revenue potential.
• Initiation of a $100.0 million stock repurchase program, with $25.0 million already executed, signaling management confidence and returning value to shareholders.
• Successful integration and revenue contribution from the Chemaxon acquisition, adding $5.3 million to Q2 revenue and $11.2 million to H1 revenue.
• Strategic investments in Research and Development, including AI integration across the product portfolio, to enhance offerings.
• Reduced interest expense due to a decline in market interest rates and a reduced base margin rate from term loan refinancing.

Negatives

• A net loss of $2.0 million was reported for Q2 2025, despite being a significant improvement from the prior year.
• Net Retention Rate for Q2 2025 slightly decreased to 107.6% from 108.0% in Q2 2024, and Q1 2025 saw a more notable decrease to 102.4% from 114.1% in Q1 2024.
• Increased cash used in investing activities, primarily due to a $3.5 million increase in capitalized software development costs.
• Increased cash used in financing activities, largely driven by the $25.0 million stock repurchase program and higher contingent consideration payments.
• The effective income tax rate for Q2 2025 was 131% and 74% for H1 2025, indicating a high tax burden relative to pre-tax income.

Risks

• Any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development.
• Ability to compete within the market.
• Changes or delays in government regulation relating to the biopharmaceutical industry.
• Trends in research and development (R&D) spending, the use of third parties by biopharmaceutical companies, and a shift toward more R&D occurring at smaller biotechnology companies.
• Consolidation within the biopharmaceutical industry.
• Ability to successfully increase customer base, expand relationships, and enter new markets.
• Ability to retain key personnel or recruit additional qualified personnel.
• Risks related to the mischaracterization of independent contractors.
• Any delays or defects in the release of new or enhanced software or other biosimulation tools.
• Issues relating to the use of artificial intelligence and machine learning in products and services.
• Failure of existing customers to renew software licenses or any delays or terminations of contracts or reductions in scope of work by existing customers.
• Risks related to contracts with government customers, including the ability of third parties to challenge the receipt of such contracts.
• Ability to sustain historic growth rates.
• Any future acquisitions and the ability to successfully integrate such acquisitions.
• The accuracy of addressable market estimates.
• Ability to successfully operate a global business.
• Adverse global economic conditions, including inflation, tariffs and/or trade disputes, and fluctuating interest rates.
• Ability to comply with applicable anti-corruption, trade compliance, and economic sanctions laws and regulations.
• Risks related to litigation.
• The adequacy of insurance coverage and the ability to obtain adequate insurance coverage in the future.
• Ability to perform services in accordance with contractual requirements, regulatory standards, and ethical considerations.
• The loss of more than one major customer.
• The ability or inability of bookings to accurately predict future revenue and the ability to realize the anticipated revenue reflected in bookings.
• Any disruption in the operations of third-party providers who host software solutions or any limitations on their capacity or interference with use.
• Ability to reliably meet data storage and management requirements, or the experience of any failures or interruptions in the delivery of services over the internet.
• Any unauthorized access to or use of customer or other proprietary or confidential data or other breach of cybersecurity measures.
• The occurrence of natural disasters, pandemics, epidemic diseases, and public health crises.
• Ability to comply with the terms of any licenses governing the use of third-party open source software utilized in software solutions.
• Ability to comply with applicable privacy and cybersecurity laws.
• Ability to adequately enforce or defend ownership and use of intellectual property and other proprietary rights.
• Any allegations of infringing, misappropriating, or otherwise violating a third party's intellectual property rights.
• Ability to meet the obligations under current or future indebtedness as they become due.
• Any limitations on the ability to pursue business strategies due to restrictions under current or future indebtedness or inability to comply with any restrictions under such indebtedness.
• Any impairment of goodwill or other intangible assets.
• The accuracy of estimates and judgments relating to critical accounting policies and any changes in financial reporting standards or interpretations.
• Any inability to design, implement, and maintain effective internal controls when required by law, or inability to timely remediate internal controls that are deemed ineffective.
• A review process initiated in 2024 to evaluate long-term strategic options for the regulatory services business could result in potential directions with significant operational impact.
• New U.S. federal administration's reforms in the pharmaceutical industry, particularly focusing on drug pricing and accelerated drug approval, are expected to potentially have a significant impact, creating a mix of opportunities and challenges.

Future Outlook

The company plans to continue investing in scientific talent, sales and marketing, and research and development, including further integration of AI across its product portfolio, expecting headcount and total operating expenses to increase. AI predictive models are anticipated to enhance the accuracy and usefulness of biosimulation models and be broadly utilized in drug development. The company is currently evaluating the impact of the recently enacted 'One Big Beautiful Bill Act' (OBBBA) on U.S. tax law and is reviewing long-term strategic options for its regulatory services business.

Management Comments

• Our goal is to enable the life science industry to use data, modeling, and analytics to make better decisions during drug development and commercialization to increase productivity rates and vastly reduce development costs.
• We believe that AI predictive models will continue to enhance the accuracy and usefulness of biosimulation models and will be utilized broadly across drug development.
• With continued innovation in and adoption of our biosimulation software, technology, and services, we believe more life science companies worldwide will leverage more of our end-to-end platform to reduce cost, accelerate speed to market, and ensure safety and efficacy of medicines for all patients.
• We continually seek and assess a range of highly focused opportunities in our immediately addressable market and in related adjacent markets, whether through acquisitions, licenses, or partnerships.

Industry Context

The biopharmaceutical industry faces high R&D costs, averaging $6.2 billion per FDA-approved drug, including failures, with annual R&D spending exceeding $270 billion. Model-Informed Drug Development (MIDD) and biosimulation are gaining increasing acceptance from regulatory bodies like the FDA and European Medicines Agency, driving demand for solutions that optimize drug discovery and development. The integration of AI and machine learning is a key trend, expected to enhance biosimulation accuracy and streamline reporting. Additionally, potential reforms in the U.S. pharmaceutical industry by the new federal administration, particularly concerning drug pricing and accelerated drug approval, could introduce both opportunities and challenges.

Comparison to Industry Standards

• Customers leveraging our solutions have received 90% or more of all new drug approvals by the FDA since 2014, indicating a strong success rate for clients utilizing our technology.
• Our software products are licensed by over 94,000 users and adopted by 23 global drug regulatory agencies, including the FDA and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), demonstrating broad market penetration and regulatory acceptance.

Corporate Governance

Legal Proceedings

• No material changes to legal proceedings as previously disclosed in the 2024 Annual Report.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, return to profitability, and the ongoing stock repurchase program, which enhances shareholder value.
• Employees: Continued investment in R&D and commercial organization indicates growth and potential for increased headcount and career opportunities.
• Customers: Enhanced software offerings, including AI integration, and continued investment in technology-enabled services aim to provide better solutions for drug development, potentially accelerating their programs and reducing costs.
• Creditors: The company remains in compliance with its debt covenants, indicating financial stability and responsible debt management.

Next Steps

• Continue to invest in scientific talent, sales and marketing, and research and development efforts.
• Further integrate artificial intelligence and machine learning across software and services portfolios.
• Evaluate the impact of the recently enacted 'One Big Beautiful Bill Act' (OBBBA) on tax law changes.
• Continue the review process for long-term strategic options for the regulatory services business.
• Continue the stock repurchase program, with approximately $75.0 million remaining available.
• Make quarterly principal payments of $750,000 on term loans, which began September 30, 2024.
• New interest rate swap agreements, each with a notional amount of $115.0 million, will become effective on August 31, 2025.

Key Dates

Recommendation

The company has demonstrated exceptional financial turnaround, moving from a substantial net loss to profitability in the first half of the year, coupled with robust revenue growth across both software and services segments. The significant increase in operating cash flow highlights improved operational efficiency. Strategic investments in AI and successful acquisitions are driving future growth. The ongoing stock repurchase program signals strong management confidence and commitment to shareholder value. These factors collectively present a compelling investment opportunity.

Keywords

Biosimulation, Drug Development, Pharmaceutical R&D, Life Sciences, Software, Technology-enabled Services, Model-Informed Drug Development, AI, Machine Learning, Cheminformatics, Regulatory Science, SEC Filing, Quarterly Report, Financial Results